An early study with chimeric receptors between the alpha2c-adrenergic receptor and m3-muscarinic receptor suggested the possible heterodimerization between GPCR types. Direct evidence for GPCR ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The anti-xerostomia effects of muscarinic agonists (cholinomimetics) are reviewed. Cevimeline (cevimeline monohydrochloride hemihydrate) is a novel muscarinic agonist that stimulates salivary ...

The M1/M4 muscarinic receptor agonist is vying to be the first drug to reach the market for schizophrenia with a new mechanism of action in decades. It is also in phase 3 clinical testing as an ...

(“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio ... M1 and dual M1/M4 receptor agonists discovered by Nxera for the treatment of schizophrenia ...

NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective ...

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...